HOME
login
history
all enzymes
BRENDA home
History
Information on EC 1.13.11.33 - arachidonate 15-lipoxygenase
for references in articles please use BRENDA:EC1.13.11.33Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.13.11.33 arachidonate 15-lipoxygenaseIUBMB Comments
The product is rapidly reduced to the corresponding 15S-hydroxy compound.
Specify your search results
Word Map
- 1.13.11.33
- lipoxygenases
-
15-hete
-
polyunsaturated
-
eicosanoids
-
leukotriene
- hydroperoxide
-
12-lipoxygenase
-
cyclooxygenases
-
15s-hydroxyeicosatetraenoic
-
lipoxins
-
hetes
- ndga
-
nordihydroguaiaretic
- alox15b
-
lipid-peroxidating
- 12/15-lipoxygenase
-
leukocyte-type
-
13-s-hydroxyoctadecadienoic
- medicine
-
platelet-type
- drug development
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Synonyms
15-lox, 15-lo-1, 15-lox-2, 15-lox2, soybean 15-lipoxygenase, 15-lipoxygenase-2, 15lo1, 15-hlo, 15-hlo-1, 15-lipoxygenase 1, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
12/15-lipoxygenase
12/15-LO
12/15-LOX
12/15LO
15-lipoxygenase
15-lipoxygenase 1
15-lipoxygenase 2
15-lipoxygenase type 1
15-lipoxygenase-1
15-lipoxygenase-2
15-LO
15-LO-1
15-LOX
15-LOX-1
15-LOX-2
15-LOX2
Alox15
arachidonic acid 15-lipoxygenase
arachidonic acid 15-lipoxygenase-1
linoleic acid omega-6-lipoxygenase
-
-
-
-
LOX2
LoxA
omega-6 lipoxygenase
-
-
-
-
oxygenase, arachidonate 15-lip-
-
-
-
-
additional information
15-lipoxygenase
-
-
-
-
15-lipoxygenase
-
-
15-lipoxygenase-1
-
-
15-LO-1
-
-
15-LOX
-
-
-
-
15-LOX-1
-
-
15-LOX-2
-
-
arachidonic acid 15-lipoxygenase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
important role of Leu597 in the mechanism of lipoxygenases
-
arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
the reaction proceeds via hydrogen abstraction, peroxide cleavage, radical rearrangement, and epoxide formation. To initiate the reaction the ferrous LOX is first activated by peroxide-dependent oxidation to a ferric form. The lipohydroperoxidase activity is initiatedwhen a lipid hydroperoxide (ROOH) is bound at the active site of the enzyme. The enzyme then catalyzes a homolytic cleavage of the hydroperoxy bond, which leads to the formation of an oxygen-centered alkoxy radical, a hydroxyl and oxidizes the ferrous iron to a ferric form. Then the enzyme binds a linoleic acid molecule (or an alterative reductant such as guaiacol) and releases a carbon-centered linoleic radical. This reaction reduces the ferric LOX back to its ferrous form to start the next catalytic cycle. The released radical intermediates may then initiate free radical secondary reactions leading to the formation of mixed oxygenated and non-oxygenated linoleic acid dimer
-
arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
the reaction proceeds via hydrogen abstraction, peroxide cleavage, radical rearrangement, and epoxide formation. To initiate the reaction the ferrous LOX is first activated by peroxide-dependent oxidation to a ferric form. The lipohydroperoxidase activity is initiatedwhen a lipid hydroperoxide (ROOH) is bound at the active site of the enzyme. The enzyme then catalyzes a homolytic cleavage of the hydroperoxy bond, which leads to the formation of an oxygen-centered alkoxy radical, a hydroxyl and oxidizes the ferrous iron to a ferric form. Then the enzyme binds a linoleic acid molecule (or an alterative reductant such as guaiacol) and releases a carbon-centered linoleic radical. This reaction reduces the ferric LOX back to its ferrous form to start the next catalytic cycle. The released radical intermediates may then initiate free radical secondary reactions leading to the formation of mixed oxygenated and non-oxygenated linoleic acid dimer
-
arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
the reaction proceeds via hydrogen abstraction, peroxide cleavage, radical rearrangement, and epoxide formation. To initiate the reaction the ferrous LOX is first activated by peroxide-dependent oxidation to a ferric form. The lipohydroperoxidase activity is initiatedwhen a lipid hydroperoxide (ROOH) is bound at the active site of the enzyme. The enzyme then catalyzes a homolytic cleavage of the hydroperoxy bond, which leads to the formation of an oxygen-centered alkoxy radical, a hydroxyl and oxidizes the ferrous iron to a ferric form. Then the enzyme binds a linoleic acid molecule (or an alterative reductant such as guaiacol) and releases a carbon-centered linoleic radical. This reaction reduces the ferric LOX back to its ferrous form to start the next catalytic cycle. The released radical intermediates may then initiate free radical secondary reactions leading to the formation of mixed oxygenated and non-oxygenated linoleic acid dimer
-
arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
the reaction proceeds via hydrogen abstraction, peroxide cleavage, radical rearrangement, and epoxide formation. To initiate the reaction the ferrous LOX is first activated by peroxide-dependent oxidation to a ferric form. The lipohydroperoxidase activity is initiatedwhen a lipid hydroperoxide (ROOH) is bound at the active site of the enzyme. The enzyme then catalyzes a homolytic cleavage of the hydroperoxy bond, which leads to the formation of an oxygen-centered alkoxy radical, a hydroxyl and oxidizes the ferrous iron to a ferric form. Then the enzyme binds a linoleic acid molecule (or an alterative reductant such as guaiacol) and releases a carbon-centered linoleic radical. This reaction reduces the ferric LOX back to its ferrous form to start the next catalytic cycle. The released radical intermediates may then initiate free radical secondary reactions leading to the formation of mixed oxygenated and non-oxygenated linoleic acid dimer
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
dioxygenation
-
-
-
-
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
arachidonate:oxygen 15-oxidoreductase
The product is rapidly reduced to the corresponding 15S-hydroxy compound.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
82249-77-2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(16(R),5Z,8Z,11Z,14Z)-16-fluoroeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 78% of the 15,16(R) product and 22% of the 12,16(R) product
-
?
(16(R),5Z,8Z,11Z,14Z)-16-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme and mutant enzyme I593A prouce small amounts of unspecific products. Mutant enzyme F353L produces 6% of 15,16(R) product and 94% of the 12,16(R) product
-
?
(16(S),5Z,8Z,11Z,14Z)-16-fluoroeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 69% of the 15,16(S) product and 31% of the 12,16(S) product
-
?
(16(S)5Z,8Z,11Z,14Z)-16-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 93% of the 15,16(S) product and 7% of the 12,16(S) product
-
?
(17(R),5Z,8Z,11Z,14Z)-17-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 1% of the 15,17(R) product and 99% of the 12,17(R) product
-
?
(17(S),5Z,8Z,11Z,14Z)-17-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 3% of the 15,17(S) product and 97% of the 12,17(S) product
-
?
(18(R),5Z,8Z,11Z,14Z)-18-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
oxygenation proceeds with little if any enantioselectivity
-
-
?
(18(S),5Z,8Z,11Z,14Z)-18-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
oxygenation proceeds with little if any enantioselectivity
-
-
?
1-linoleoyl lysophosphatidic acid + O2
(S)-hydroperoxy 1-linoleoyl lysophosphatidic acid
-
i.e. linoleoyl-lysoPA
major product
-
?
1-linoleoyl lysophosphatidylcholine + O2
(S)-hydroperoxy 1-linoleoyl lysophosphatidylcholine
-
i.e. linoleoyl-lysoPC
major product
-
?
1-palmitoyl-2-arachidonyl phosphatidyl choline + O2
15S-HpETE
-
-
-
-
?
1-palmitoyl-2-docosahexaenoyl phosphatidyl choline + O2
17S-HpDHE
-
-
-
-
?
1-palmitoyl-2-eicosapentaenoyl phosphatidyl choline + O2
15S-HpEPE
-
-
-
-
?
1-palmitoyl-2-linoleoyl phosphatidyl choline + O2
(9E,11E)-13S-hydroperoxy-9,11-octadecadienoic acid
-
-
-
-
?
1-stearyl-2-linoleoyl glycerol + O2
cholesteryl-(9E,11E)-13S-hydroperoxy-9,11-octadecadienoate
-
-
-
-
?
11,14,17-eicosatrienoic acid + O2
15-hydroperoxy-11,13,17-eicosatrienoic acid
-
-
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
8,11,14-eicosatrienoic acid + O2
15-hydroperoxy-8,11,13-eicosatrienoic acid
-
-
-
?
alpha-linoleic acid + O2
?
72% activity compared to arachidonate
-
-
?
alpha-linolenate + O2
(9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid + (9Z,11E,13S,15Z)-13-hydroxyoctadeca-9,11,15-trienoic acid
arachidonate + O2
(5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
ratio of (5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate to (5Z,8Z,11Z,13E,15R)-15-hydroperoxyicosa-5,8,11,13-tetraenoate is 92:8
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid + (12S,5Z,8Z,10E,14Z)-12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid
arachidonic acid + O2
13-hydroperoxyeicosatetraenoic acid + (5Z,8Z,11R,12E,14Z)-11-hydroperoxyicosa-5,8,12,14-tetraenoic acid + (5Z,8E,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
arachidonic acid + O2
15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid
-
-
-
-
?
cholesteryl linoleate + O2
cholesteryl-(9E,11E)-13S-hydroperoxy-9,11-octadecadienoate
-
-
-
-
?
dihomo-gamma-linolenic acid + O2
?
44% activity compared to arachidonate
-
-
?
dilinoleoyl phosphatidic acid + O2
(S)-hydroperoxy dilinoleoyl phosphatidic acid
-
i.e. dilinoleoylPA
-
-
?
dilinoleoyl phosphatidylcholine + O2
(S)-hydroperoxy dilinoleoyl phosphatidylcholine
-
i.e. dilinoleoylPC
-
-
?
docosahexaenoic acid + O2
?
72% activity compared to arachidonate
-
-
?
eicopentanoic acid + O2
?
61% activity compared to arachidonate
-
-
?
eicosadienoic acid + O2
?
33% activity compared to arachidonate
-
-
?
gamma-linolenic acid + O2
?
44% activity compared to arachidonate
-
-
?
linoleate + O2
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate + (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoate + (9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate
linoleic acid + O2
13(S)-hydroxyoctadecadienoic acid
-
-
12/15LO eicosanoid products reduce cholesterol efflux to high density lipoproteins, regulate ATP-binding cassette transporter G1 expression and enhance ATP-binding cassette transporter G1 degradation and ATP-binding cassette transporter G1 serine phosphorylation
-
?
linoleic acid + O2
13-S-hydroxyoctadecadienoic acid
-
both 15-LOX-1, 15-LOX-2 reacts with linoleic acid poorly
-
-
?
linolenate + O2
11-hydroperoxyoctadecatrienoic acid + 9-hydroperoxyoctadecatrienoic acid + 13-hydroperoxyoctadecatrienoic acid
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview, i.e. 15(S)-HPETE and 15(S)-HETE, the first is the predominant product
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview, i.e. 15(S)-HPETE and 15(S)-HETE, the first is the predominant product
-
?
alpha-linolenate + O2
(9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid + (9Z,11E,13S,15Z)-13-hydroxyoctadeca-9,11,15-trienoic acid
-
-
-
-
?
alpha-linolenate + O2
(9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid + (9Z,11E,13S,15Z)-13-hydroxyoctadeca-9,11,15-trienoic acid
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
671247, 672376, 672543, 672899, 672902, 673030, 675201, 675909, 676263, 676923, 676925, 676927, 677239, 685266, 685525, 685526, 685584, 686173, 687052, 687235, 688159, 688509, 688751, 712712
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
and small amounts of (5Z,8Z,10E,14Z)-12-hydro(pero)xy-5,8,10,14-icosatetraenoic acid
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid + 15-hydroxy-5,8,11,13-eicosatetraenoic acid
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
formation of 15S-hydroxyeicosatetraenoic acid and 12S-hydroxyeicosatetraenoic acid in a ratio of 12:1, double oxygenation products 14R,15S-dihydroxyeicosatetraenoic acid and various 8,15-dihydroxyeicosatetraenoic acids are also produced
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
ratio of 15-lipoxygenation to 12-lipoxygenation is 9:1 for the wild-type enzyme and the mutant enzymes V104I, L397M and Q431R. The ratio of 15-lipoxygenation to 12-lipoxygenation is 1:1 for the mutant enzymes V104/L397M/M418V/Q431R, L397M/M418V/Q431R, L397M/M418V and M418V
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
15-hydroxyeicosatetraenoic acid and 12-hydroxyeicosatetraenoic acid in a ratio of 8.6:1
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
further metabolized to (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate, 15-HETE, has no effect on the spontaneous and lipopolysaccharide-stimulated growth of leukemic blasts
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)-HPETE, further reduced to the correspondent (S)-hydroxy fatty acids, in eosinophils, overview, the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)HPETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
is further metabolized to (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells, it could be a suppressor of prostate cancer development, which functions by restricting cell cycle progression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is implicated in inflammatory disorders, 15-lipoxygenase is induced in atherosclerosis and can oxidize low-density lipoprotein to its atherogenic form
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
alternative splicing of 15S-lipoxygenase provides a further level of regulation of fatty acid metabolism
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
12/15LO protein levels and activity are increased in pathologically affected regions of Alzheimer’s disease brains, enzyme inhibition causes a decrease in amyloid-beta protein, 12/15LO influences amyloid-beta protein precursor protein metabolism, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
15-lipoxygenase type-1 is a prooxidant enzyme, which is expressed in asthmatic lungs leading to formation of pro- and anti-inflammatory mediators, overview
the product is further metabolized to 15(S)-hydroxyeicosatetranoic acid and 15-ketoeicosatetraenoic acid, the latter is the main product, pathway and mechanism, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
15-LOX2 in NHP cells is positively regulated by Sp1 and negatively regulated by Sp3, but 15-LOX2 expression in NHP cells is not directly regulated by androgen/androgen receptor, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid is metabolized by the 15-lipoxygenase-1 pathway to the vasodilatory eicosanoids hydroxyepoxyeicosatrienoic acid and trihydroxyeicosatrienoic acid
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid metabolization by lipoxygenases, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is involved in acetylsalicylic acid-triggered production of 15(S)-hydroxyeicosatetranoic acid, 15(S)-HETE, in sensitive asthmatic patients, acetylsalicylate-tolerant asthma patients show reduced 15-LO activity
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme modifies high density lipoprotein 3, the major and most antiatherogenic HDL subfraction, and impairs anti-inflammatory activity of the lipoprotein, which, after modification, fails to inhibit TNFalpha-mediated mRNA and protein induction of adhesion molecules and monocyte chemoattractant protein-1, MCP-1, in endothelial cells, overview
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
immunohistochemic assay
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
preferred substrate of isozyme 15-hLO-2, reaction of EC 1.13.11.33
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
regioselective oxidation is achieved through control over the position of hydrogen atom abstraction by the geometry and size of the enzyme active site and through control by the protein over the interaction of molecular oxygen with the generated delocalized substrate radical, analysis of catalytic mechanisms of lipoxygenases using 10,10-dideuterated arachidonic acid, 13,13-dideuterated arachidonic acid, and 0,10,13,13-d4-AA, overview
isozymes 15-hLO-1 and 15-hLO-2 also form small amounts of 11-HPETE, 8-HPETE, and 12-HPETE, the rate of 8/12-HPETE production by isozyme 15-hLO-1 with 13,13-dideuterated arachidonic acid as substrate is exeptionally high with 75% of overall production, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
and nonenzymatic production of 15-hydroxy-5,8,11,13-eicosatetraenoic acid, 15-keto-5,8,11,13-eicosatetraenoic acid, 13-hydroxy-14,15-epoxy-5,8,11-eicosatrienoic acid and 11,14,15-trihydroxy-5,8,12-eicosatrienoic acid
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
is further metabolized by hydroperoxide isomerase to the acid-sensitive metabolite 15(S)-hydroxy-11,12-epoxyeicosatrienoic acid, which is hydrolyzed to 11,12,15-trihydroxyeicosatrienoic acid, by a soluble epoxid hydrolase, causing endothelium-dependent smooth muscle hyperpolarization and relaxations, mass spectrometrical metabolite analysis and pathway, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
first step in biotransformation of arachidonic acid to the 15-series of leukotrienes, reaction is involved in inactivation of slow-reacting substrances of anaphylaxis
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
high oxygen affinity is important for effective catalysis, L367 is involved in oxygen access, channel structure, overview, arachidonic acid closes the substrate-binding pocket for oxygen diffusion but opens a fourth oxygen access channel
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
15-H(p)ETE is the major reaction product of 15-LOX-2 and 12/15-LOX independent of the pH
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
product ratio is 9 to 1
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
5fold higher affinity for arachidonic acid than for linoleic acid for 15-hLO-1
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
both 15-LOX-1 and -2
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
main product is 12(S)-hydroxyeicosatetranoic acid
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
G1S6D2
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
15-H(p)ETE is the major reaction product independent of the pH
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
H2QBX9
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
12/15LO eicosanoid products reduce cholesterol efflux to high density lipoproteins, regulate ATP-binding cassette transporter G1 expression and enhance ATP-binding cassette transporter G1 degradation and ATP-binding cassette transporter G1 serine phosphorylation
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
-
the mutant enzyme A416G converts arachidonic acid to (11R)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid and (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid in a 1.5:1 ratio
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
-
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
an atomic-level study of the binding modes of linoleic acid to rabbit reticulocyte 15-rLO-1 is presented. Results are compared with binding of arachidonic acid to 15-rLO-1. Linoleic acid seems to adapt more easily to the enzyme structure and differs from arachidonic acid on some dynamical aspects that could introduce kinetic differences, as observed experimentally
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
-
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid + (12S,5Z,8Z,10E,14Z)-12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid
-
93% (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid and 7% (12S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid + (12S,5Z,8Z,10E,14Z)-12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid
-
-
the ratio of (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid to (12S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid is 20 for the wild-type enzyme
-
?
arachidonic acid + O2
13-hydroperoxyeicosatetraenoic acid + (5Z,8Z,11R,12E,14Z)-11-hydroperoxyicosa-5,8,12,14-tetraenoic acid + (5Z,8E,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
B7JX99
-
-
-
?
arachidonic acid + O2
13-hydroperoxyeicosatetraenoic acid + (5Z,8Z,11R,12E,14Z)-11-hydroperoxyicosa-5,8,12,14-tetraenoic acid + (5Z,8E,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
Cyanothece sp. ATCC 51142 PCC 8801
B7JX99
-
-
-
?
linoleate + O2
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate + (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoate + (9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate
B7JX99
-
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate is the primary product
-
?
linoleate + O2
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate + (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoate + (9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate
Cyanothece sp. ATCC 51142 PCC 8801
B7JX99
-
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate is the primary product
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
reaction of EC 1.13.11.12
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
-
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
preferred substrate of isozyme 15-hLO-1, reaction of EC 1.13.11.12
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
78% activity compared to arachidonate
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate
-
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
13-hydroperoxy-9,11-octadecadienoic acid + 13-hydroxy-9,11-octadecadienoic acid
?
linoleic acid + O2
?
-
an atomic-level study of the binding modes of linoleic acid to rabbit reticulocyte 15-rLO-1 is presented. Results are compared with binding of arachidonic acid to 15-rLO-1. Linoleic acid seems to adapt more easily to the enzyme structure and differs from arachidonic acid on some dynamical aspects that could introduce kinetic differences, as observed experimentally
-
-
?
linolenate + O2
11-hydroperoxyoctadecatrienoic acid + 9-hydroperoxyoctadecatrienoic acid + 13-hydroperoxyoctadecatrienoic acid
B7JX99
-
-
-
?
linolenate + O2
11-hydroperoxyoctadecatrienoic acid + 9-hydroperoxyoctadecatrienoic acid + 13-hydroperoxyoctadecatrienoic acid
Cyanothece sp. ATCC 51142 PCC 8801
B7JX99
-
-
-
?
additional information
?
-
B7JX99
incubation of the enzyme with [(11S)-2H]-linoleic acid leads to the formation of hydroperoxides that have lost the deuterium label, thus suggesting that LOX2 catalyzes antarafacial oxygenation as opposed to the mechanism of manganese lipoxygenase
-
-
-
additional information
?
-
Cyanothece sp. ATCC 51142 PCC 8801
B7JX99
incubation of the enzyme with [(11S)-2H]-linoleic acid leads to the formation of hydroperoxides that have lost the deuterium label, thus suggesting that LOX2 catalyzes antarafacial oxygenation as opposed to the mechanism of manganese lipoxygenase
-
-
-
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
-
additional information
?
-
-
15-LOX2 and 15-LOX2sv-b suppress prostate tumor development, and the tumor-suppressive functions apparently do not necessarily depend on arachidonic acid-metabolizing activity and nuclear localization
-
-
-
additional information
?
-
-
15-LOX2 is a functional tumor suppressor that regulates prostate epithelial cell differentiation, senescence, and growth size, overview
-
-
-
additional information
?
-
-
eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in eosinophils and mast cells, metabolism of 14,15-leukotrienes in eosinophils, overview
-
-
-
additional information
?
-
a bifunctional enzyme exhibiting 12-LO and 15-LO activity
-
-
-
additional information
?
-
-
a bifunctional enzyme exhibiting 15-lipoxygenase and 12-lipoxygenase, EC 1.13.11.31, activities
-
-
-
additional information
?
-
-
conjugated linoleic acids are no substrates for 15-LO-1 in vitro, overview
-
-
-
additional information
?
-
-
product distributions of lipoxygenases under various conditions, overview
-
-
-
additional information
?
-
-
substrate specificity of 15-hLO isozymes, the specific activity is affected by cholate and lipoxygenation reaction products, e.g. 13-hydroperoxyoctadienoic acid changes the (kcat/Km)AA/(kcat/Km)LA ratio more than 5fold for 15-hLO-1 and 3fold for 15-hLO-2, while 12-(S)-hydroperoxyeicosatetraenoic acid affects only the ratio of 15-hLO-1 more than 5fold. In addition, 13-(S)-hydroxyoctadecadienoic acid and 12-(S)-hydroxyeicosatetraenoic acid also affect substrate specificity, indicating that iron oxidation is not responsible for the change in the (kcat/Km)AA/(kcat/Km)LA ratio, residues R402, F414, F352, I417, and M418 are located at the active site and involved in catalysis, presence of a product-activated, allosteric regulatory site for both 15-hLO isozymes, competitive substrate capture experiments, overview
-
-
-
additional information
?
-
-
15-LOX-2 does not oxygenate (5Z,8Z,11Z,14Z)-nonadeca-5,8,11,14-tetraene-1,19-dioic acid at various pH
-
-
-
additional information
?
-
-
15LO1 interacts with PEBP1 (phosphatidylethanolamine-binding protein)
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type subject produces 21% 12-hydroperoxyicosatetraenoate and 79% 15-hydroperoxyicosatetraenoate
-
-
-
additional information
?
-
-
15-LOX is a non-heme iron-containing dioxygenase that oxygenates polyunsaturated fatty acids (PUFA) containing cis,cis-1,4-pentadiene moieties
-
-
-
additional information
?
-
human 15-LOX type 1 (ALOX15) is a predominantly 15-lipoxygenating enzyme, which produces only little amounts of (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate (ratio of 9:1)
-
-
-
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation. Intraenzyme oxygen movement
-
-
-
additional information
?
-
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification
-
-
-
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
-
specificity of phospholipid binding by 15-LOX-2, overview
-
-
-
additional information
?
-
the enzymatic peroxidation reaction consists of four consecutive steps: At first a hydrogen atom is stereoselectively abstracted from one of the bisallylic methylene-groups forming an enzyme-bound radical. Secondly one of the two associated cis-double bonds is rearranged and forms a conjugated cis-trans-diene. Consecutively a peroxy radical is produced by inserting molecular oxygen. Finally the radical is reduced by antarafacial re-inserting of a hydrogen atom. The resulting product of this peroxidation reaction depends on the respective fatty acid, which is used as a substrate
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
the enzyme also converts linoleate to (9Z,11E,13S)-13-hydroperoxy-11,13-octadecadienoate
-
-
-
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
-
a bifunctional enzyme exhibiting 12-LO and 15-LO activity, the enzyme is also able to catalyze stereoselective oxidation of linoleic acid at position 13 over 9 to preferentially form 13(S)-hydroperoxyoctadienoic acid, which enhances MCP-1 expression, overview
-
-
-
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
-
additional information
?
-
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
-
additional information
?
-
the enzymatic peroxidation reaction consists of four consecutive steps: At first a hydrogen atom is stereoselectively abstracted from one of the bisallylic methylene-groups forming an enzyme-bound radical. Secondly one of the two associated cis-double bonds is rearranged and forms a conjugated cis-trans-diene. Consecutively a peroxy radical is produced by inserting molecular oxygen. Finally the radical is reduced by antarafacial re-inserting of a hydrogen atom. The resulting product of this peroxidation reaction depends on the respective fatty acid, which is used as a substrate
-
-
-
additional information
?
-
-
a bifunctional enzyme exhibiting 12-LO and 15-LO activity, the enzyme is also able to catalyze stereoselective oxidation of linoleic acid at position 13 over 9 to preferentially form 13(S)-hydroperoxyoctadienoic acid, which enhances MCP-1 expression, overview
-
-
-
additional information
?
-
G1S6D2
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 54% 12-hydroperoxyicosatetraenoate and 46% 15-hydroperoxyicosatetraenoate with 76% overall activity compared to the human enzyme activity
-
-
-
additional information
?
-
G1S6D2
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
the enzyme also converts linoleate to (9Z,11E,13S)-13-hydroperoxy-11,13-octadecadienoate, alpha-linolenate to (9Z,11E,13S,15Z)-13-hydroperoxy-9,11,15-octadecatrienoate and gamma-linolenate to (6Z,9Z,11E,13S)-13-hydroperoxy-6,9,11-octadecatrienoate
-
-
-
additional information
?
-
-
15-lipoxygenase is capable of disrupting the pH gradient maintained by mitochondria in living cells without additional factors specific for red blood cell development. Ectopic expression of 15-lipoxygenase leads to the collaps of the mitochondrial pH gradient in nonerythroid cells
-
-
-
additional information
?
-
-
activation of the enzyme at the protein and product levels and increased sensitivity to constriction of pulmonary arteries by the product 15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid may contribute to pulmonary hypoxic vasoconstriction in neonatal rabbits
-
-
-
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
-
additional information
?
-
-
stereo-selectivity in LOX-catalyzed oxygenation of lysophospholipids, overview
-
-
-
additional information
?
-
-
the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)HPETE
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. The wild-type animal produces 3% 12-hydroperoxyicosatetraenoate and 97% 15-hydroperoxyicosatetraenoate
-
-
-
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
-
additional information
?
-
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Molecular docking studies of a phospholipid molecule at the active site of rabbit ALOX15. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
-
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
H2QBX9
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 20% 12-hydroperoxyicosatetraenoate and 80% 15-hydroperoxyicosatetraenoate with 135% overall activity compared to the human enzyme activity
-
-
-
additional information
?
-
H2QBX9
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 78% 12-hydroperoxyicosatetraenoate and 22% 15-hydroperoxyicosatetraenoate with 37% overall activity compared to the human enzyme activity
-
-
-
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 14% 12-hydroperoxyicosatetraenoate and 86% 15-hydroperoxyicosatetraenoate
-
-
-
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
-
additional information
?
-
-
production of antiinflammatory lipid mediators by the enzyme may be a general strategy by which pathogens regulate the host-pathogen relationship
-
-
-
additional information
?
-
enzyme LoxA is capable of efficiently catalyzing the peroxidation of a broad range of free fatty acid substrates, e.g. arachidonate and linoleate with high positional specificity, indicating a 15-LOX, its mechanism includes hydrogen atom abstraction. LoxA also does not react with 5- or 15-15-hydroperoxyicosatetraenoates, or phosphoester fatty acids
-
-
-
additional information
?
-
-
trans-10,cis-12-conjugated linoleic acid is not a substrate for 15-LOX-1
-
-
-
additional information
?
-
-
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
-
additional information
?
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
-
additional information
?
-
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
-
-
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
further metabolized to (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate, 15-HETE, has no effect on the spontaneous and lipopolysaccharide-stimulated growth of leukemic blasts
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)-HPETE, further reduced to the correspondent (S)-hydroxy fatty acids, in eosinophils, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
O15296
15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells, it could be a suppressor of prostate cancer development, which functions by restricting cell cycle progression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is implicated in inflammatory disorders, 15-lipoxygenase is induced in atherosclerosis and can oxidize low-density lipoprotein to its atherogenic form
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
alternative splicing of 15S-lipoxygenase provides a further level of regulation of fatty acid metabolism
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
12/15LO protein levels and activity are increased in pathologically affected regions of Alzheimer’s disease brains, enzyme inhibition causes a decrease in amyloid-beta protein, 12/15LO influences amyloid-beta protein precursor protein metabolism, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
15-lipoxygenase type-1 is a prooxidant enzyme, which is expressed in asthmatic lungs leading to formation of pro- and anti-inflammatory mediators, overview
the product is further metabolized to 15(S)-hydroxyeicosatetranoic acid and 15-ketoeicosatetraenoic acid, the latter is the main product, pathway and mechanism, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
15-LOX2 in NHP cells is positively regulated by Sp1 and negatively regulated by Sp3, but 15-LOX2 expression in NHP cells is not directly regulated by androgen/androgen receptor, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid is metabolized by the 15-lipoxygenase-1 pathway to the vasodilatory eicosanoids hydroxyepoxyeicosatrienoic acid and trihydroxyeicosatrienoic acid
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid metabolization by lipoxygenases, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is involved in acetylsalicylic acid-triggered production of 15(S)-hydroxyeicosatetranoic acid, 15(S)-HETE, in sensitive asthmatic patients, acetylsalicylate-tolerant asthma patients show reduced 15-LO activity
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme modifies high density lipoprotein 3, the major and most antiatherogenic HDL subfraction, and impairs anti-inflammatory activity of the lipoprotein, which, after modification, fails to inhibit TNFalpha-mediated mRNA and protein induction of adhesion molecules and monocyte chemoattractant protein-1, MCP-1, in endothelial cells, overview
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
is further metabolized by hydroperoxide isomerase to the acid-sensitive metabolite 15(S)-hydroxy-11,12-epoxyeicosatrienoic acid, which is hydrolyzed to 11,12,15-trihydroxyeicosatrienoic acid, by a soluble epoxid hydrolase, causing endothelium-dependent smooth muscle hyperpolarization and relaxations, mass spectrometrical metabolite analysis and pathway, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
first step in biotransformation of arachidonic acid to the 15-series of leukotrienes, reaction is involved in inactivation of slow-reacting substrances of anaphylaxis
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
P16050
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
F7EPQ4
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
P39654
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
P39654
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
P39654
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
G1S6D2
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
H2QBX9
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
A0A096P2G1
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
Q5RBE8
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
Q5RBE8
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
Q9I4G8
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
Q02759
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
Q02759
-
-
-
?
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
-
additional information
?
-
-
15-LOX2 and 15-LOX2sv-b suppress prostate tumor development, and the tumor-suppressive functions apparently do not necessarily depend on arachidonic acid-metabolizing activity and nuclear localization
-
-
-
additional information
?
-
-
15-LOX2 is a functional tumor suppressor that regulates prostate epithelial cell differentiation, senescence, and growth size, overview
-
-
-
additional information
?
-
-
eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in eosinophils and mast cells, metabolism of 14,15-leukotrienes in eosinophils, overview
-
-
-
additional information
?
-
-
15LO1 interacts with PEBP1 (phosphatidylethanolamine-binding protein)
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type subject produces 21% 12-hydroperoxyicosatetraenoate and 79% 15-hydroperoxyicosatetraenoate
-
-
-
additional information
?
-
-
15-LOX is a non-heme iron-containing dioxygenase that oxygenates polyunsaturated fatty acids (PUFA) containing cis,cis-1,4-pentadiene moieties
-
-
-
additional information
?
-
P16050
human 15-LOX type 1 (ALOX15) is a predominantly 15-lipoxygenating enzyme, which produces only little amounts of (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate (ratio of 9:1)
-
-
-
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation. Intraenzyme oxygen movement
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
F7EPQ4
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
-
additional information
?
-
G1S6D2
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 54% 12-hydroperoxyicosatetraenoate and 46% 15-hydroperoxyicosatetraenoate with 76% overall activity compared to the human enzyme activity
-
-
-
additional information
?
-
-
15-lipoxygenase is capable of disrupting the pH gradient maintained by mitochondria in living cells without additional factors specific for red blood cell development. Ectopic expression of 15-lipoxygenase leads to the collaps of the mitochondrial pH gradient in nonerythroid cells
-
-
-
additional information
?
-
-
activation of the enzyme at the protein and product levels and increased sensitivity to constriction of pulmonary arteries by the product 15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid may contribute to pulmonary hypoxic vasoconstriction in neonatal rabbits
-
-
-
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. The wild-type animal produces 3% 12-hydroperoxyicosatetraenoate and 97% 15-hydroperoxyicosatetraenoate
-
-
-
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
-
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
H2QBX9
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 20% 12-hydroperoxyicosatetraenoate and 80% 15-hydroperoxyicosatetraenoate with 135% overall activity compared to the human enzyme activity
-
-
-
additional information
?
-
A0A096P2G1
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 78% 12-hydroperoxyicosatetraenoate and 22% 15-hydroperoxyicosatetraenoate with 37% overall activity compared to the human enzyme activity
-
-
-
additional information
?
-
Q5RBE8
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
-
additional information
?
-
Q5RBE8
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 14% 12-hydroperoxyicosatetraenoate and 86% 15-hydroperoxyicosatetraenoate
-
-
-
additional information
?
-
-
production of antiinflammatory lipid mediators by the enzyme may be a general strategy by which pathogens regulate the host-pathogen relationship
-
-
-
additional information
?
-
-
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
additional information
?
-
Q02759
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
-
additional information
?
-
Q02759
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
Fe
Fe2+
Iron
Mg2+
Ca2+
-
enhances activity, reversible by EGTA, inhibited by phosphatidyl serine and phosphatidyl choline
Ca2+
-
in the presence of Ca2+, with or without calcium ionophore, the majority of 15-LO-1 is found in the membrane fraction, although significant amounts are also detected in the supernatant fraction
Ca2+
-
Ca2+ binds to the PLAT domain of 15-LOX-2, resulting in a translocation from the cytosol to the membrane
Ca2+
-
for maximal intracellular activity, 12/15-lipoxygenases require a rise in cytosolic calcium concentration inducing a translocation of the enzyme from the cytosol to cellular membranes
Fe2+
B7JX99
LOX2 contains iron with an iron to protein ratio of 45%
Fe2+
-
addition in a molar excess, more than 50:1 purified protein:Fe2+, leads to a 3fold increase in the specific activity
Fe2+
-
required for the catalytic cycle of fatty acid oxidation by lipoxygenase, overview
Fe2+
-
required, iron content of the 15-hLO isozymes determined with a Finnigan inductively coupled plasma mass spectrometer, ICP-MS, using cobalt-EDTA as an internal standard
Iron
-
the recombinant enzyme contains a variable amount of iron, often as low as 0.2 mol per mol of enzyme
Iron
-
the iron is liganded by four histidines at positions 361, 366, 541 and 545 asell as the C-terminal isoleucine
Mg2+
-
in the presence of Mg2+, with or without calcium ionophore, the majority of 15-LO-1 is found in the membrane fraction, although significant amounts are also detected in the supernatant fraction
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(-)-5,7-O-diacetyl-3',4',5'-O-triacetylepigallocatechin-3-O-(3'',4'',5''-O-triacetyl)gallate
-
IC50: 0.061 mM
(-)-5,7-O-dibutyryl-3',4',5'-O-tributyrylepigallocatechin-3-O-(3'',4'',5''-O-tributyryl) gallate
-
IC50: 0.033 mM
(-)-5,7-O-dimethyl-3',4',5'-O-trimethylepigallocatechin-3-O-(3'',4'',5''-O-trimethyl) gallate
-
IC50: 0.03 mM
(-)-5,7-O-dipropionyl-3',4',5'-O-tripropionylepigallocatechin-3-O-(3'',4'',5''-O-tripropionyl) gallate
-
IC50: 0.031 mM
1-(((2,4,6-trimethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.017 mM
1-(((2,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.027 mM
1-(((2,5-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.015 mM
1-(((2-methyl)ethylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.042 mM
1-(((2-methyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.022 mM
1-(((2-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.021 mM
1-(((3,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.019 mM
1-(((3-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.023 mM
1-(((4-(2-methylethyl)phenl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.016 mM
1-(((4-chlorophenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.022 mM
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.2 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.22 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methoxyphenyl)-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.2 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-dibutyl-7-indolizinecarbonitrile
-
IC50: 0.03 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diethyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarboxaldehyde
-
IC50: 0.02 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinylethanone
-
IC50: 0.023 mM
1-(((4-methysulfonyllphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(((4-trifluoromethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.023 mM
1-((4-methylphenyl)sulfonyl)2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-((N,N-dimethylaminosulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-(1,3-dibenzyloxy-2-propyloxy)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-(1-Hydroxy-1-phenyl-ethyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.017 mM
1-(2-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-(4-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.032 mM
1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one
-
1-(Cyclohexyl-hydroxy-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.023 mM
1-(Hydroxy-p-tolyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.022 mM
1-(hydroxymethyl)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.034 mM
1-(Methoxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.021 mM
1-[(2H-1,3-benzodioxol-5-yl)carbamothioyl]-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
-
1-[(4-Chloro-phenyl)-hydroxy-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.023 mM
1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
-
1-[4-[4-([[5-(3-chlorophenyl)furan-2-yl]methyl]amino)phenyl]piperazin-1-yl]ethan-1-one
-
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
-
1-[Hydroxy-(4-methoxy-phenyl)-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.017 mM
11-thialinoleic acid
-
is a noncompetitive inhibitor of 15-lipoxygenase-1 with respect to arachidonate or linoleic acid as substrates. Presence of inhibitor does not alter the product distribution for 15-lipoxygenase-1. It does not change the regioselectivity of 15-lipoxygenase-1
2,3-Dihydroxybenzoic acid
-
47.7% inhibition at 0.015 mM, active site binding structure
2,4-dihydroxybenzoic acid
-
49.9% inhibition at 0.015 mM, active site binding structure
2,5-dihydroxybenzoic acid
-
21.2% inhibition at 0.015 mM, active site binding structure
2,6-dibromo-4-[1-(3-bromo-4-hydroxyphenyl)-1-methylethyl]phenol
-
IC50: 0.005 mM
2-([4-[(4-fluorobenzyl)oxy]butyl]sulfanyl)-5-(naphthalen-1-yl)-1,3,4-oxadiazole
-
-
2-alkyl-6-hydroxy-4-H-benzopyran-4-one
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
2-hydroxybenzoic acid
-
46.0% inhibition at 0.015 mM, active site binding structure
2-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy]-N,N-dimethylethan-1-amine
-
3,4,5-Trihydroxybenzoic acid
-
60.5% inhibition at 0.015 mM, active site binding structure
3,4-dihydroxybenzoic acid
-
51.6% inhibition at 0.015 mM, active site binding structure; 73.3% inhibition at 0.015 mM, active site binding structure
3,5-Dihydroxybenzoic acid
-
58.1% inhibition at 0.015 mM, active site binding structure
3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylic acid
-
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-cyclohexylimidazo[2,1-b][1,3]thiazol-5-amine
-
-
3-(4-bromophenyl)-N-cyclohexyl-6-(2-nitrophenyl)imidazo[2,1-b][1,3]thiazol-5-amine
-
-
3-(4-methoxyphenyl)-6-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
protective activity of compound 5i against H2O2-induced cell death in differentiated PC12 cells
3-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
3-Hydroxybenzoic acid
-
47.6% inhibition at 0.015 mM, active site binding structure
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
4'-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00053 mM in the presence of arachidonate, IC50: 0.0002 mM in the presence of linoleic acid
4'-ethyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00026 mM in the presence of arachidonate, IC50: 0.00047 mM in the presence of linoleic acid
4'-tert-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00027 mM in the presence of arachidonate, IC50: 0.00023 mM in the presence of linoleic acid
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)methyl)-benzyl-4-fluorobenzoate
-
-
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(5-(3-hydroxynaphthalen-2-yl)-1,3,4-oxadiazol-2-ylthio)-but-2-ynyl-4-fluorobenzoate
-
low solubility
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylamino)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-1H-indole-4-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-benzofuran-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-thiadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
low solubility
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(3-hydroxypropyl)benzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(4-methoxyphenyl)benzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-butylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-cyclohexylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-phenylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-[3-(dimethylamino)propyl]benzamide
-
-
4-([2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]sulfamoyl)benzoic acid
-
-
4-butyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
IC50: 0.00307 mM in the presence of arachidonate, IC50: 0.004 mM in the presence of linoleic acid
4-butyl-N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]benzenesulfonamide
-
-
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide
-
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
-
4-ethyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
4-hydroxy-3-methoxybenzoic acid
-
45.4% inhibition at 0.015 mM, active site binding structure
4-hydroxybenzoic acid
-
47.0% inhibition at 0.015 mM, active site binding structure
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
-
-
4-pentyl-N-(2-[2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl]ethyl)benzenesulfonamide
-
-
4-pentyl-N-[2-(2-quinolin-3-yl-1H-indol-3-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyrazin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-3-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-[5-(1H-pyrrol-2-yl)-1H-indol-3-yl]ethyl]benzenesulfonamide
-
-
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1H-imidazole-4-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluoropyridine-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-methoxybenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trichlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trifluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chloro-1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(difluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(methylsulfonyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(triazan-2-yl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-bromobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-chloro-3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-[(trifluoromethyl)sulfanyl]benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclobutanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopentanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopropanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl furan-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl naphthalene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl thiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]butyl 4-fluorobenzoate
-
-
4-[[5-(naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-chlorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-methoxybenzoate
-
-
6,7-diphenylpyrrolo[1,2-b]pyridazin-5-yl trifluoromethanesulfonate
-
IC50: 0.043 mM
6-(2-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
-
6-(4-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
-
6-[4-([1,1'-biphenyl]-2-yl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
-
6-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]-1-phenylhexan-1-one
-
low solubility
7,8-dihydroxy-3'-trifluoromethylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
7-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
-
alpha-mangostin
-
NSC30552, a natural product, caspase-3 pathway inhibitor, performs selective inhibition of 12-LO
arachidonic acid
-
autoinactivates 15-hLO-1 to a much greater extent than linoleic acid at high substrate concentrations. No autoinactivation at low substrate concentrations
conjugated linoleic acids
-
conjugated linoleic acids may function as inhibitors of 15-LO-1 activity in macrophages/in vivo, overview
-
ethyl 6-([3-[(2-chloro-4-fluorophenyl)carbamoyl]-1H-pyrazole-1-carbonyl]amino)hexanoate
-
-
GATA-6
-
inhibits non-steroidal anti-inflammatory drugs-induced transcription of 15-LOX-1 in colorectal cancer cells
-
methyl 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
-
methyl 3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylate
-
-
michellamine B
-
NSC661755, potent but non-selective inhibitor, a natural anti-viral agent
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-(2-chloro-4-fluorophenyl)-1-[3-(trifluoromethyl)benzene-1-sulfonyl]-1H-pyrazole-3-carboxamide
-
-
N-(2-chloro-4-fluorophenyl)-4,5-bis(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
-
N-(2-chloro-4-fluorophenyl)-4-methyl-5-(trimethylsilyl)-1H-pyrazole-3-carboxamide
-
-
N-(2-chloro-4-fluorophenyl)-4-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
-
N-(2-chloro-4-fluorophenyl)-5-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
-
N-(4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol)-2-ylthio)but-2-ynyl-thiophene-2-carboxamide
-
-
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
-
-
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
-
-
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
-
-
N-[(5-bromo-8-hydroxy-5,6,7,8-tetrahydroquinolin-7-yl)(thiophen-2-yl)methyl]acetamide
-
N-[2-(1H-indol-3-yl)ethyl]-2'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00092 mM in the presence of arachidonate, IC50: 0.00046 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-3'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00045 mM in the presence of arachidonate, IC50: 0.00032 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-(1-methylethyl)biphenyl-4-sulfonamide
-
IC50: 0.00028 mM in the presence of arachidonate, IC50: 0.00014 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-(2-methylpropyl)biphenyl-4-sulfonamide
-
IC50: 0.00091 mM in the presence of arachidonate, IC50: 0.00017 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-methoxybiphenyl-4-sulfonamide
-
IC50: 0.0015 mM in the presence of arachidonate, IC50: 0.00109 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00047 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-methylbenzenesulfonamide
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
IC50: 0.00042 mM in the presence of arachidonate, IC50: 0.00102 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-propylbenzenesulfonamide
-
IC50: 0.00313 mM in the presence of arachidonate, IC50: 0.0032 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.0034 mM in the presence of arachidonate, IC50: 0.0042 mM in the presence of linoleic acid
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-dibenzo[b,d]furan-2-yl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1-methyl-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-(hydrazinocarbonyl)benzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-bromobenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pyridin-4-ylbenzenesulfonamide
-
-
N-[2-[2-(2,5-dimethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(2-methyl-1,3-thiazol-4-yl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-chlorophenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-ethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]biphenyl-4-sulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methylphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
-
-
N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]-4-pentylbenzenesulfonamide
-
-
N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]biphenyl-4-sulfonamide
-
-
N1-(2H-1,3-benzodioxol-5-yl)-N-3-(2-chloro-4-fluorophenyl)-1H-pyrazole-1,3-dicarboxamide
-
-
N3-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)-N1-hexyl-5-methyl-1H-pyrazole-1,3-dicarboxamide
-
-
N3-(2-chloro-4-fluorophenyl)-N1-hexyl-4-methyl-1H-pyrazole-1,3-dicarboxamide
-
-
neodysidenin
-
natural product from marine sponge Dysidea herbacea from Papua New Guinea, extraction and purification, overview, steady-state inhibition kinetics, competitive mode of inhibition, selective for 12-LO
RINKKIEK
-
68.1% inhibition at 0.25 mM, a beta-casein-derived octapeptide
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.037mM
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.035 mM
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.048 mM
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.075 mM
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.039 mM
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
-
IC50: 0.059 mM
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
-
IC50: 0.059 mM